- Home
- SISI vs HOTH Comparison
SISI vs HOTH Comparison
Compare SISI & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SISI
- HOTH
- Stock Information
- Founded
- SISI 1997
- HOTH 2017
- Country
- SISI China
- HOTH United States
- Employees
- SISI N/A
- HOTH N/A
- Industry
- SISI Medicinal Chemicals and Botanical Products
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- SISI Health Care
- HOTH Health Care
- Exchange
- SISI Nasdaq
- HOTH Nasdaq
- Market Cap
- SISI 227.4M
- HOTH 15.6M
- IPO Year
- SISI 2016
- HOTH 2019
- Fundamental
- Price
- SISI $7.33
- HOTH $1.75
- Analyst Decision
- SISI
- HOTH Strong Buy
- Analyst Count
- SISI 0
- HOTH 3
- Target Price
- SISI N/A
- HOTH $4.00
- AVG Volume (30 Days)
- SISI 1.6M
- HOTH 2.1M
- Earning Date
- SISI 11-13-2025
- HOTH 11-11-2025
- Dividend Yield
- SISI N/A
- HOTH N/A
- EPS Growth
- SISI N/A
- HOTH N/A
- EPS
- SISI N/A
- HOTH N/A
- Revenue
- SISI $9,601,324.00
- HOTH N/A
- Revenue This Year
- SISI N/A
- HOTH N/A
- Revenue Next Year
- SISI N/A
- HOTH N/A
- P/E Ratio
- SISI N/A
- HOTH N/A
- Revenue Growth
- SISI 1133.26
- HOTH N/A
- 52 Week Low
- SISI $4.71
- HOTH $0.65
- 52 Week High
- SISI $528.60
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- SISI 56.38
- HOTH 70.75
- Support Level
- SISI $5.02
- HOTH $1.53
- Resistance Level
- SISI $7.96
- HOTH $1.87
- Average True Range (ATR)
- SISI 0.61
- HOTH 0.14
- MACD
- SISI 0.38
- HOTH 0.05
- Stochastic Oscillator
- SISI 79.61
- HOTH 80.15
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).